![]() |
市场调查报告书
商品编码
1880633
安全胰岛素笔针市场规模、占有率、成长及全球产业分析:依类型、应用和地区划分的洞察与预测(2024-2032 年)Safety Pen Needles Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032 |
||||||
全球安全胰岛素笔针市场正经历稳定成长,这主要得益于糖尿病患者数量的增加、家庭医疗保健的普及以及对安全便捷的胰岛素注射设备需求的不断增长。 2024 年,该市场规模达到 7.224 亿美元,主要受全球糖尿病负担加重以及胰岛素笔在慢性病管理中广泛应用的推动。预计到 2025 年,该市场规模将达到 7.68 亿美元,并在 2032 年显着增长至 12.701 亿美元,预测期内复合年增长率 (CAGR) 为 7.5%。北美是领先地区,在2024年占全球市场占有率的42.44%。
安全胰岛素笔针是无菌一次性医疗器械,配备针头保护罩和防护罩等防护功能,可防止针刺伤。其在临床和家庭中的应用日益广泛,主要归功于其便利性、安全性以及与常用胰岛素笔的兼容性。 Envector Corporation、Cardinal Health 和 MTD Medical Technology and Devices 等领先企业持续投资于创新、合作和新产品发布,从而巩固其全球地位。
市场动态
市场推动因素
糖尿病盛行率的快速上升仍然是市场成长的主要推动因素。根据国际糖尿病联盟 (IDF) 发布的 "糖尿病地图集" (2025 年),目前 20 至 79 岁成年人中有 11.1% 患有糖尿病,这推动了对胰岛素治疗需求的成长。由于久坐的生活方式、肥胖以及快速的都市化进程,全球胰岛素使用量持续成长。随着患者和医护人员寻求更安全的注射方式,安全胰岛素笔针头逐渐取代标准胰岛素笔针头和传统注射器,成为更受欢迎的选择。
市场限制因子
先进的替代给药技术的出现对市场扩张构成了重大挑战。无针给药系统(例如鼻腔给药和喷射注射器)的创新正日益受到患者和临床医生的关注。 2024年11月,Sol Millennium Medical Group在美国推出了Insujet无针胰岛素输注装置,推动了非侵入性给药方式的转变。这可能会在未来几年限制对安全胰岛素笔针头的需求。
市场机会
家庭医疗保健正成为成长最快的市场机会领域之一。根据NCBI(2023)的数据,全球约有60%的胰岛素使用者倾向于使用胰岛素笔自我注射。老年人群体尤其受益于胰岛素笔针的便利性和安全性。远距患者护理的扩展、个人化治疗方案的推行以及小型胰岛素笔设计的普及,正在推动胰岛素笔的进一步推广。亚太和拉丁美洲等新兴市场家庭糖尿病管理的快速成长,蕴藏着巨大的未开发成长潜力。
市场挑战
安全胰岛素笔针的高昂成本仍然是其广泛应用的一大障碍。正如英国国家医疗服务体系(NHS,2025年6月)所指出的,安全胰岛素笔针的价格可能是标准针头的八倍,而且在开发中地区通常不在医疗保险范围内。在中国、印度和其他低收入市场,经济承受能力有限仍然是其使用的主要阻碍因素。
市场趋势
製造商正在整合先进的安全机制和超细针头技术,以提高舒适度和患者依从性。 4毫米长、32-34号的胰岛素笔针可以减轻注射疼痛,提升病患体验。自动回缩机制、被动式防护罩和针头隐藏系统正变得越来越受欢迎。此外,医疗器材公司和製药公司之间的合作正在扩大胰岛素和GLP-1受体激动剂更安全的注射系统范围。
2024年,北美市场将以3.066亿美元的估值引领市场,这主要得益于糖尿病的高发病率和强大的供应基础。美国对生长激素疗法的监管审批不断增加,也推动了市场需求。欧洲市场占有率位居第二,这主要归功于处方量的成长和宣传活动的扩大。亚太地区预计将实现最高的复合年增长率,这主要得益于该地区的高糖尿病发病率和新的分销合作伙伴关係。拉丁美洲以及中东和非洲地区预计将保持稳定成长,这主要得益于肥胖率的上升以及先进药物输送装置的普及。
The global safety pen needles market is witnessing consistent growth, driven by rising diabetes prevalence, expansion of home healthcare, and increasing preference for safe and convenient insulin delivery devices. The market was valued at USD 722.4 million in 2024, supported by the growing global burden of diabetes and high usage of insulin pens for chronic disease management. By 2025, the market is projected to reach USD 768.0 million, and by 2032, it is expected to expand significantly to USD 1,270.1 million, reflecting a CAGR of 7.5% during the forecast period. North America remained the dominant region in 2024, holding 42.44% of the global market share.
Safety pen needles are sterile, single-use devices engineered with protective mechanisms such as needle guards and shields to prevent accidental needlestick injuries. Their increasing adoption in clinical and home settings is largely attributed to their convenience, safety features, and compatibility with widely used insulin pens. Major companies such as Embecta Corp., Cardinal Health, and MTD Medical Technology and Devices continue to invest in technological upgrades, partnerships, and new product rollouts to strengthen their global presence.
Market Dynamics
Market Drivers
The sharp rise in diabetes prevalence remains the primary driver of market growth. The IDF Diabetes Atlas (2025) reports that 11.1% of adults aged 20-79 years are currently living with diabetes, highlighting the escalating demand for insulin therapy. Coupled with sedentary lifestyles, obesity, and rapid urbanization, the number of insulin users continues to grow worldwide. As patients and healthcare professionals seek safer injection methods, safety pen needles are increasingly preferred over standard pen needles and traditional syringes.
Market Restraints
The introduction of advanced alternative drug delivery technologies poses a significant challenge to market expansion. Innovations in needle-free systems-such as intranasal delivery and jet injectors-are gaining interest among patients and clinicians. In November 2024, Sol-Millennium Medical Group launched Insujet, a needle-free insulin delivery device in the U.S., representing a shift toward non-invasive drug delivery that may limit demand for safety pen needles in the coming years.
Market Opportunities
Home healthcare is emerging as one of the fastest-growing opportunity areas. According to NCBI (2023), around 60% of global insulin users prefer insulin pens for self-administration. The elderly population, in particular, benefits from the ease and safety of pen needles. Expanding remote patient care, personalized treatment plans, and availability of compact pen designs further support adoption. Emerging markets across Asia Pacific and Latin America are experiencing rapid increases in home-based diabetes management, presenting considerable untapped growth potential.
Market Challenges
The high cost of safety pen needles remains a barrier to widespread adoption. As noted by the NHS (June 2025), safety pen needles can be up to 8 times more expensive than standard needles and are often not reimbursed in developing regions. Limited affordability continues to restrict their use in China, India, and other low-income markets.
Market Trends
Manufacturers are integrating advanced safety mechanisms with ultra-thin needle technology to improve comfort and adherence. Pen needles with 4mm length and 32-34 gauge structures reduce injection pain and enhance patient experience. Auto-retraction, passive shielding, and hidden-needle systems are increasingly being incorporated. Furthermore, collaborations between medical device makers and pharmaceutical companies are expanding the availability of safety-enhanced injection systems for insulin and GLP-1 agonists.
North America led the market in 2024 with a valuation of USD 306.6 million, supported by high diabetes incidence and strong product availability. Increased regulatory approvals for growth hormone therapies in the U.S. also support demand. Europe held the second-largest share, with rising prescription volumes and growing awareness campaigns. Asia Pacific is projected to record the fastest CAGR, fueled by the region's high diabetes prevalence and new distribution partnerships. Latin America and Middle East & Africa are experiencing steady momentum, driven by rising obesity levels and expanding access to advanced drug delivery devices.
Conclusion
With market value rising from USD 722.4 million in 2024 to USD 1,270.1 million by 2032, the safety pen needles market demonstrates strong long-term growth potential. Demand will continue to be shaped by diabetes prevalence, home-care expansion, product innovation, and strategic industry partnerships, even as needle-free technologies create competitive pressure.
Segmentation By Product Type, Drug Type, Disease Indication, Needle Size, Distribution Channel, and Region
By Product Type * Active Safety Pen Needles
By Drug Type * Insulin
By Disease Indication * Diabetes
By Needle Size * 4 mm
By Distribution Channel * Hospital Pharmacy
By Region * North America (By Product Type, Drug Type, Disease Indication, Needle Size, Distribution Channel, and Country/Sub-region)
U.S.
Canada
U.K.
Germany
France
Italy
Spain
Scandinavia
Rest of Europe
China
Japan
India
Australia
Southeast Asia
Rest of Asia Pacific
Brazil
Mexico
Rest of Latin America
GCC
South Africa
Middle East & Africa